Oral Anticoagulation in Haemodialysis Patients

  • End date
    Jan 23, 2023
  • participants needed
  • sponsor
    University Hospital, Strasbourg, France
Updated on 23 September 2021


Guidelines recommend oral anticoagulation with vitamin K antagonists for atrial fibrillation whenever the CHADS2VASC score is superior or equal to 2. As there are no specific guidelines for the hemodialysis patients with atrial fibrillation, the general guidelines apply. However, several retrospective studies suggest that these patients do not benefit from the oral anticoagulation regarding the risk of stroke and may even experience more bleedings and deaths.

The aim of this prospective study is to prospectively compare the hemorrhagic and thrombotic risks of oral anticoagulation in comparison with no anticoagulation in hemodialysis patients with atrial fibrillation.

Condition Chronic renal failure, end stage renal disease, chronic renal disease, end-stage renal disease, esrd, end-stage renal failure, end stage kidney disease, end stage renal failure
Treatment No oral anticoagulation, Oral anticoagulation with vitamin K antagonists
Clinical Study IdentifierNCT02886962
SponsorUniversity Hospital, Strasbourg, France
Last Modified on23 September 2021


Yes No Not Sure

Inclusion Criteria

Adult patients ( 18 years)
Patient on hemodialysis treatment for at least 1 month
Patient with a history of, or presenting a new episode of atrial fibrillation (either permanent or paroxysmal)
Patient with a CHADS2VASC score 2
Patient with high risk of bleeding as defined by (1) HASBLED score 3 OR (2) HASBLED CHADS2VASC score, OR (3) recent history of severe bleeding (type 3a, 3b, 3c), particularly cerebral or gastrointestinal, OR (4) prior recurrent (>2) history of falls
Patient capable of understanding information about the study and of giving his/her consent
Patient informed of the preliminary medical exam results
Patient with healthcare insurance
Written consent signed

Exclusion Criteria

Formal indication to oral anticoagulation beside atrial fibrillation (mechanic heart valves, recurrent thrombophlebitis, antiphospholipid syndrome)
Life expectancy < 6 months (e.g., terminal cancer)
Live donor transplantation scheduled within 6 months
Pregnancy (-HCG blood-based assay)or nursing (lactating) women
Women of child bearing potential, unless they are using an effective method of birth control
Patient under legal guardianship
Patients under law protection
Known hypersensibility to coumadin or indoine derivatives or to any excipients (CI to oral AVK)
Severe liver failure (CI to oral AVK)
Clear my responses

How to participate?

Step 1 Connect with a site
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact


Preferred Language
Other Language
Please verify that you are not a bot.

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note